AGP Executive Report
Last update: 2 hours agoSwiss Finance & Insurance: AM Best affirmed Zurich Insurance Group’s A+ (Superior) financial strength and “aa” long-term issuer credit ratings, with a stable outlook, citing very strong balance sheet strength and risk management ahead of Zurich’s planned Beazley acquisition. Swiss Health & Pharma: Novartis’ experimental pelacarsen failed to cut major heart attack and stroke risk in a late-stage trial despite lowering lipoprotein(a), a setback for its cardiovascular pipeline. Swiss Economy & Society: Switzerland’s gender pay gap keeps narrowing, and the country is moving toward a nationwide conversion therapy ban. Swiss Business & Media: Swiss Films says homegrown and co-produced titles are expanding internationally, with more English-language works drawing attention at major festivals including Venice. Swiss Lifestyle & Cities: A Zürich IT professional is commuting by swimming through the city’s moat, turning a personal routine into a viral story about urban nature. Global Trade Watch (relevant to Swiss firms): Canada and the U.S. are not planning to resume trade talks before Ottawa’s retaliatory tariffs take effect, raising the risk of deeper tariff escalation.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
